Journal
PHARMACEUTICS
Volume 13, Issue 8, Pages -Publisher
MDPI
DOI: 10.3390/pharmaceutics13081193
Keywords
blood-brain barrier; nanomedicine; liposome; brain tumor; exosome; glioblastoma multiforme
Categories
Funding
- Ministry of Science and Technology, Taiwan [109-2321-B-001-012, 109-2327-B-001-001, 109-2740-B-001-002, MOST 110-2740-B-001-003, MOST 109-2636-B-038-003]
- National Health Research Institutes [EX109-10907SI]
- Academia Sinica Healthy Longevity Grand Challenge [AS-HLGC-109-05]
- Translational Medical Research Program [AS-KPQ-110-BioMed]
- Taipei Medical University-CWRU Pilot Program [108-3805-023-400]
Ask authors/readers for more resources
Treatment of brain tumors is challenging due to the blood-brain tumor barrier, but nanomedicines show promise despite being underutilized in clinical settings. Liposomes, extracellular vesicles, and biomimetic strategies are the most clinically feasible nano-carrier strategies for improving brain drug delivery. Numerous obstacles in translation of these technologies include pre-clinical models, analytical methods, and regulatory issues.
Treatment of brain tumors is challenging since the blood-brain tumor barrier prevents chemotherapy drugs from reaching the tumor site in sufficient concentrations. Nanomedicines have great potential for therapy of brain disorders but are still uncommon in clinical use despite decades of research and development. Here, we provide an update on nano-carrier strategies for improving brain drug delivery for treatment of brain tumors, focusing on liposomes, extracellular vesicles and biomimetic strategies as the most clinically feasible strategies. Finally, we describe the obstacles in translation of these technologies including pre-clinical models, analytical methods and regulatory issues.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
